Versant Capital Management, Inc Mirati Therapeutics, Inc. Transaction History

Versant Capital Management, Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 10, 2023	BUY	$36.13 - $49.49 $325 - $445	9 Added 180.0%	14 $0
Q1 2023 Apr 10, 2023	SELL	$36.54 - $54.26 $511 - $759	-14 Reduced 73.68%	5 $0
Q4 2022 Jan 25, 2023	SELL	$41.27 - $98.62 $1,403 - $3,353	-34 Reduced 64.15%	19 $0
Q3 2022 Dec 30, 2022	BUY	$59.5 - $86.7 $1,725 - $2,514	29 Added 120.83%	53 $4,000
Q2 2022 Aug 02, 2022	BUY	$39.16 - $88.71 $939 - $2,129	24 New	24 $2,000
Q1 2022 Apr 29, 2022	SELL	$75.82 - $150.97 $4,473 - $8,907	-59 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$132.13 - $177.45 $7,267 - $9,759	55 Added 1375.0%	59 $10,000
Q1 2021 Apr 27, 2021	BUY	$158.92 - $221.61 $635 - $886	4 New	4 $1,000
Q1 2020 Apr 17, 2020	SELL	$69.78 - $116.21 $628 - $1,045	-9 Closed	0 $0
Q4 2019 Jan 28, 2020	SELL	$70.76 - $128.86 $212 - $386	-3 Reduced 25.0%	9 $1,000
Q3 2019 Oct 18, 2019	BUY	$77.91 - $109.6 $934 - $1,315	12 New	12 $0
Q2 2019 Jul 16, 2019	SELL	$59.49 - $104.71 $237 - $418	-4 Closed	0 $0
Q1 2019 Apr 23, 2019	BUY	$43.65 - $78.95 $174 - $315	4 New	4 $0
Q1 2019 Apr 23, 2019	BUY	$43.65 - $78.95 $0 - $0	0 New	0 $0

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Versant Capital Management, Inc with notifications on news.